Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
(NASDAQ:DERM),(NASDAQ:FBIO), SCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) — Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its third quarter 2025 financial […]